Taysha Gene Therapies, Inc. (TSHA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.60+0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TSHA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete dosing and report topline data from REVEAL pivotal and ASPIRE trials, advance BLA-enabling activities, and engage FDA for BLA submission pathway.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Management completed dosing in the REVEAL pivotal trial with 17 patients and ASPIRE trial dosing is ongoing. They expect topline data and FDA feedback on the BLA submission pathway in the first half of 2027 and anticipate completing the BLA-enabling PPQ campaign in Q4 2026. The trajectory is delivering consistent progress toward clinical development and regulatory milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Completed dosing in REVEAL pivotal and ASPIRE trials; topline data and FDA feedback expected 1H 2027; BLA-enabling PPQ campaign ongoing.”
“Reaffirmed FDA alignment on BLA pathway; advanced dosing in REVEAL pivotal trial; initiated BLA-enabling PPQ campaign.”
Prepare for potential TSHA-102 launch by advancing market access planning and expanding manufacturing partnership with Catalent.
Stated in 2 quarters including 2026-Q1 and 2026-Q2. Management has advanced commercial readiness activities and expanded the partnership with Catalent to support future commercial manufacturing. While no specific revenue or volume milestones are reported, the expanded partnership and increased commercial launch-related expenses indicate progress in preparing for potential product launch.
“Advanced TSHA-102 commercial readiness activities and expanded partnership with Catalent for commercial manufacturing.”
“Increased consulting and professional fees including commercial launch-readiness initiatives.”
Ensure sufficient cash runway through capital raises and disciplined spending to support operations through potential BLA approval in second half of 2028.
Stated in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Management completed a $230 million follow-on offering in 2026-Q2, increasing cash and cash equivalents from $276.6 million in 2026-Q1 to $455.4 million in 2026-Q2. They expect current cash resources to support operations into the second half of 2028, aligning with the planned timeline for potential BLA approval. The trajectory shows delivering on financial resource maintenance.
“Completed $230 million follow-on offering; cash runway extended into second half of 2028.”
“Cash resources sufficient to fund planned operating expenses into 2028.”
“Cash resources expected to support operations into 2028.”
Continue to show TSHA-102 is generally well tolerated with no severe treatment-related serious adverse events or dose-limiting toxicities across trials.
Stated in 3 quarters including 2026-Q1 and 2026-Q2. Management consistently reports TSHA-102 is generally well tolerated with no severe treatment-related serious adverse events or dose-limiting toxicities across multiple trials and data cutoffs. This recurring safety profile statement is supported by clinical trial data and shows delivering on safety and tolerability.
“TSHA-102 generally well tolerated with no severe treatment-related SAEs or DLTs across trials as of August 2026 data cutoff.”
“No treatment-related SAEs or DLTs in REVEAL Phase 1/2 and pivotal trials as of May 2026 data cutoff.”
Continue clinical trials and regulatory engagement for TSHA-102 gene therapy in Rett syndrome, including pivotal and safety trials and BLA submission preparation.
Over the trailing year it converted 2.45x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
4 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.